Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076396 · ClinicalTrials.gov registry record · Phase 1
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by PharmaMar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT05076396: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by PharmaMar.
NCT05076396 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by PharmaMar. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05076396, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by PharmaMar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tumors.
Primary Outcome
To identify the dose limiting toxicities (DLTs), and to determine the maximun tolerated dose (MTD) and the recommended dose (RD) of PM14 administered i.v. on two days (Day 1 and Day 8) or on Day 1 only, both every three weeks (q3wk) over three hours to patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG PM14
Study Locations (9)
Madrid
- Hospital General Universitario Gregorio Marañón - Madrid
- Clinica Universidad de Navarra - Madrid
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Madrid Sanchinarro - Madrid
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- MD Anderson Cancer Center - Houston
París
- Gustave Roussy - Villejuif
Catalonia
- Hospital Universitari Vall d'Hebron - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2025-08-13 |
| Phase | Phase 1 |
What NCT05076396 shows while recruiting
NCT05076396 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PM14 is the first listed.
NCT05076396 lists 9 locations in 5 states (Madrid, Massachusetts, Texas).
Frequently Asked Questions
What is clinical trial NCT05076396 about?
NCT05076396 is a clinical study titled "PM14 Administered Intravenously to Patients with Advanced Solid Tumors". Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new ...
What is the current status of trial NCT05076396?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2017-09-06. Estimated completion is 2025-08-13.
What conditions does trial NCT05076396 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05076396?
The interventions under investigation include: PM14 (DRUG).
Who is sponsoring clinical trial NCT05076396?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05076396 being conducted?
This trial has 9 study locations across Massachusetts, Texas, París, Catalonia, Madrid. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05076396's enrollment target sits among peer trials
150 86th of 189 higher than 100 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI